Bispecific Antibody Therapies in Multiple Myeloma

Both community and academic nurses must know what to expect and how to react to adverse events from bispecific antibody treatment in myeloma; however, Donna Catamero, ANP-BC, OCN, CCRC, notes this can be predictable for providers.

A group of oncology advanced practice providers discussed the use of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma.

A poll of experts revealed that few are utilizing talquetamab for patients with pretreated relapsed/refractory myeloma.

“Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high-risk myeloma.